Steroid eye drops do help with dry eye, particularly when inflammation is a driving factor. A large Cochrane review pooling data from multiple trials found that topical corticosteroids produce a small to moderate improvement in both patient-reported symptoms and measurable corneal damage compared to lubricant drops alone. That said, steroids are not a first-line, long-term fix for dry eye. They work best as a short burst to knock down inflammation, used alongside or as a bridge to other therapies, because extending their use raises real risks to the eye.
Why Dry Eye Involves Inflammation in the First Place
Dry eye is often described as a tear problem, but the tears are only part of the story. The ocular surface runs on a delicate feedback loop: when the tear film breaks down, the exposed surface becomes hyperosmolar (too salty), which triggers an inflammatory response. That inflammation damages the surface cells that produce and stabilize tears, which makes the tear film break down further, which drives more inflammation. Researchers call this the “vicious circle” of dry eye disease, and it applies whether the root cause is insufficient tear production or problems with the oil glands in the eyelids (meibomian gland dysfunction).
1PubMed Central. Revisiting the vicious circle of dry eye disease: a focus on the pathophysiology of meibomian gland dysfunctionThis inflammatory component is exactly what steroids target. Corticosteroids are potent anti-inflammatory agents that suppress a wide range of immune signals on the ocular surface. By breaking the cycle at its inflammatory node, steroids can give the surface a chance to heal and allow other treatments to work more effectively. The question has never really been whether steroids reduce inflammation on the eye; it is whether they do so safely enough and with a large enough benefit to justify the risks for a chronic condition like dry eye.
How Much Do They Actually Help
The most comprehensive look at this question comes from a Cochrane systematic review of randomized trials. When corticosteroid drops were compared head-to-head with lubricant drops (artificial tears), the steroid group scored meaningfully better on patient-reported symptom questionnaires and on clinical measures of corneal surface damage (fluorescein staining). The reviewers rated this as moderate-certainty evidence, meaning they were fairly confident the benefit is real, though the size of the effect could shift with future studies.
2PubMed Central. Topical corticosteroids for dry eyeThe same review found that steroids may slightly improve tear film break-up time, which is a measure of how long the tear film holds together between blinks, but the evidence there was weaker. And for tear osmolarity, a lab measure of how concentrated the tears are, there was no convincing difference at all. So steroids appear to help the surface heal and reduce the discomfort patients feel, but they do not fundamentally fix the tear composition itself.
2PubMed Central. Topical corticosteroids for dry eyeIndividual trials paint a consistent picture. One study using low-dose preservative-free hydrocortisone found significant reductions in both redness and symptom scores, along with a measurable increase in tear film thickness after four weeks of treatment.
3PubMed. Topical Low Dose Preservative-Free Hydrocortisone Reduces Signs and Symptoms in Patients with Chronic Dry Eye: A Randomized Clinical TrialAnother trial using 0.1% fluorometholone in patients with moderate to severe dry eye who had not responded well to artificial tears found that symptoms improved within a week and objective clinical signs improved within a month.
4PubMed Central. A clinical study of the efficacy of topical corticosteroids on dry eyeIt is worth noting, though, that the broader dry eye treatment landscape has a quality-of-evidence problem. The TFOS DEWS II report, a major international guideline effort, observed that many treatments for dry eye lack the rigorous Level 1 evidence that would make them easy to recommend with full confidence. This applies to steroids as well as to most other options.
5PubMed. TFOS DEWS II Management and Therapy ReportWhich Steroids Get Used and How They Differ
Not all steroid eye drops are the same. Eye doctors choose among several formulations based on how much anti-inflammatory punch they need and how concerned they are about side effects. The steroids most commonly discussed for dry eye include fluorometholone, loteprednol etabonate, hydrocortisone, and clobetasone butyrate. These tend to be lower-potency or “soft” steroids, meaning they are designed to work on the surface and break down quickly once they penetrate deeper into the eye. This matters because many steroid side effects are tied to how much drug reaches the interior of the eye.
Loteprednol etabonate gets a lot of attention in the dry eye world. In a rat model of dry eye induced by a common preservative, loteprednol performed just as well as the stronger steroid prednisolone acetate at reducing signs of disease.
6PubMed. Comparison of prednisolone acetate and loteprednol etabonate for the treatment of benzalkonium chloride-induced dry eye syndrome in ratsIn clinical practice, loteprednol is favored partly because it has a lower risk profile for pressure elevation in the eye. A systematic review found that steroids with lower anti-inflammatory potency and reduced ability to penetrate inside the eye carry less risk of raising intraocular pressure.
7PubMed. Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic reviewHow doctors schedule the drops also varies. Some prescribe a short daily course for two to four weeks. Others use a “pulsed” regimen, where the drops are used for a brief window, stopped, and then used again if inflammation returns. A study of pulsed therapy with preservative-free hydrocortisone in patients with Sjögren syndrome-related dry eye found that this approach improved both signs and symptoms without affecting intraocular pressure.
8PubMed. Short-term results of a pulsed therapy with hydrocortisone eye drops to treat moderate to severe dry eye in primary Sjögren syndrome patientsWhy Preservatives in the Bottle Matter
This is an underappreciated detail. Many standard steroid eye drops contain preservatives like benzalkonium chloride (BAK), which itself can irritate the ocular surface and worsen dry eye over time. If you are putting drops in your eyes specifically because the surface is inflamed and damaged, having a chemical in those drops that further damages the surface is counterproductive.
A trial comparing preservative-free methylprednisolone to preserved prednisolone (in the context of eye inflammation, not specifically dry eye) found that patients using the preservative-free version had significantly less corneal staining and reported less discomfort.
9Cornea. Comparison of Efficacy and Ocular Surface Toxicity of Topical Preservative-free Methylprednisolone and Preserved Prednisolone in the Treatment of Acute Anterior UveitisFor dry eye patients, who already have a compromised ocular surface, choosing a preservative-free formulation can make a meaningful difference in comfort and surface health during treatment.
The Pressure Problem
The biggest reason steroid eye drops are not used casually or long-term for dry eye is their potential to raise intraocular pressure (IOP). Elevated pressure inside the eye, if sustained, can damage the optic nerve and lead to glaucoma, which causes irreversible vision loss. This connection between steroids and eye pressure has been recognized since the 1950s.
10PubMed Central. Steroid-induced Glaucoma: An Avoidable Irreversible BlindnessThe risk is not uniform across all patients or all steroids. It climbs with prolonged use, higher dosing frequency, younger age, and more potent formulations.
7PubMed. Risk of intraocular pressure elevation after topical steroids in children and adults: A systematic reviewA retrospective study of topical periocular steroid use found that, overall, there was no significant pressure change across the group. However, eyes that started with higher baseline pressure did see a meaningful increase, and one patient had a clinically significant pressure spike of 7 mm Hg.
11Ophthalmic Plastic & Reconstructive Surgery. Effect of Topical Periocular Steroid Use on Intraocular Pressure: A Retrospective AnalysisThe practical takeaway is that anyone using steroid eye drops needs regular pressure checks. Most eye doctors will schedule a follow-up within two to four weeks of starting a steroid drop, and sooner for patients who have risk factors like a family history of glaucoma. If pressure starts climbing, the drops are tapered or switched to something with a lower penetration profile.
Cataract Risk With Extended Use
Steroid use is also linked to a specific type of cataract called a posterior subcapsular cataract (PSC). These form on the back surface of the lens and can blur vision, particularly for reading and in bright light. The connection between prolonged glucocorticoid use and PSC cataracts is well established.
12PubMed. What causes steroid cataracts? A review of steroid-induced posterior subcapsular cataractsWhat makes this risk tricky is that researchers have struggled to pin down a “safe” dose or duration. A study comparing patients with and without a history of steroid therapy found a significant difference in PSC rates between the two groups, but no clear relationship between total dose, weekly dose, or duration and the likelihood of developing cataracts. The researchers concluded that individual susceptibility may be the most important factor, and they recommended abandoning the concept of a safe dose altogether.
13JAMA Ophthalmology. Effect of Corticosteroids on Cataract FormationFor the short courses typically used in dry eye management, the cataract risk is generally considered low. But for patients who find themselves needing repeated steroid bursts over months or years, the cumulative exposure becomes a concern that needs to be weighed against the benefits.
Other Side Effects Worth Knowing
Beyond pressure and cataracts, steroid eye drops carry a list of less common but real risks. A comprehensive review of locally administered ocular corticosteroids identified issues including tear-film instability (ironic, given that this is the very problem you are trying to fix), toxicity to the surface epithelium, weakened wound healing, and, with very long-term use, orbital fat atrophy and drooping of the upper eyelid.
14PubMed. Locally administered ocular corticosteroids: benefits and risksOne risk that deserves particular emphasis is that steroids can mask the signs of an active infection. If you have an eye infection that has been mistaken for or is coexisting with dry eye, putting a steroid drop on it can suppress the immune response and let the infection worsen silently. This is why your eye doctor will typically examine you before prescribing a steroid and will want follow-up visits during treatment. It is also why using leftover steroid drops from a previous prescription without a fresh evaluation is a bad idea.
Dry Eye Subtypes That Respond Particularly Well
Not everyone with dry eye has the same disease. The condition splits broadly into aqueous-deficient dry eye (you do not make enough tears) and evaporative dry eye (your tears evaporate too fast, usually because the oily outer layer is deficient). Many people have a mix of both. Steroids can help either type when inflammation is prominent, but the evidence is particularly encouraging for two scenarios.
The first is meibomian gland dysfunction (MGD), the leading cause of evaporative dry eye. A randomized study found that adding loteprednol 0.5% to standard warm compresses and lid hygiene significantly reduced inflammatory markers in the tears and improved tear film stability, oil gland function, and overall MGD severity compared to warm compresses alone.
15PubMed Central. Dry Eye Disease Associated with Meibomian Gland Dysfunction: Focus on Tear Film Characteristics and the Therapeutic LandscapeThe second is dry eye associated with Sjögren syndrome, an autoimmune condition that attacks moisture-producing glands throughout the body. A trial of clobetasone butyrate drops in Sjögren patients showed significant improvements in corneal and conjunctival staining by day 15, and by day 30, symptom scores and inflammatory markers on the eye surface were significantly better than baseline.
16PubMed. Safety and efficacy of 0.1% clobetasone butyrate eyedrops in the treatment of dry eye in Sjögren syndromeHow Steroids Fit With Other Anti-Inflammatory Treatments
Steroids are rarely the whole plan. In current practice, they are most often used as a short-term induction treatment to rapidly suppress inflammation while a slower-acting anti-inflammatory agent is started for the long haul. The two most common long-term options are cyclosporine (sold as Restasis or Cequa) and lifitegrast (Xiidra), both of which dampen the immune response on the eye surface through different mechanisms than steroids. These drugs take weeks to months to reach full effect, and patients often feel worse before they feel better because of initial stinging and irritation. A brief course of steroids can cover that gap, providing comfort while the maintenance therapy ramps up.
A European expert panel’s consensus recommendations addressed exactly this stepwise approach, advocating for the strategic use of topical corticosteroids alongside cyclosporine to manage inflammation in dry eye disease.
17PubMed Central. Management of inflammation in dry eye disease: Recommendations from a European panel of expertsOne older clinical study directly compared steroids to nonsteroidal anti-inflammatory drops (NSAIDs) and artificial tears in dry eye patients. Patients receiving a steroid regimen of fluorometholone had significantly lower symptom severity, less corneal staining, and fewer inflammatory cells on the surface compared to both the NSAID group and the artificial tears group at 15 and 30 days. However, none of the treatments improved Schirmer test results, which measure baseline tear production.
18PubMed. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical studyThis reinforces the idea that steroids address the inflammatory component of dry eye very effectively but do not fix underlying tear production deficits.
The Practical Reality of Using Eye Drops
All of the clinical evidence assumes patients are actually using their drops as directed, and the data on adherence is not especially reassuring. A web-based survey of dry eye patients found that roughly six in ten were using their drops only when they felt symptoms, rather than on the prescribed schedule.
19PubMed Central. Adherence to Eye Drops Usage in Dry Eye Patients and Reasons for Non-Compliance: A Web-Based SurveyCommon reasons included forgetting to carry the drops, feeling that the prescribed frequency was too high, and stopping early because symptoms improved.
Adherence challenges extend to steroid drops specifically. A study of patients using corticosteroid drops (for uveitis, but the logistical barriers are the same) found that over half were using drops more than once a day, and about one in eight said the frequency itself was a barrier to sticking with the plan. Nearly a quarter occasionally ran out of drops before their next refill. Physical factors mattered too: about four in ten had trouble reading the small print on the bottles, and nearly one in five said poor vision made it hard to aim drops into the eye.
20PubMed Central. Barriers to Adherence with Corticosteroid Eye Drops in Patients with UveitisFor steroid drops in dry eye, where the course is typically short and the dosing schedule usually reasonable (once or twice daily for a few weeks), the adherence bar is lower than for a chronic medication. But the temptation to keep using a steroid that is making your eyes feel better, or to restart it without a checkup when symptoms flare, is real. That kind of unmonitored extended use is precisely where the risks of pressure elevation and cataracts come into play. If you find yourself reaching for steroid drops more than a couple of times a year, it is a signal to revisit your treatment plan rather than keep refilling.
When Steroid Drops Are Not the Right Choice
There are situations where steroid eye drops should be avoided or used only with extreme caution. Active eye infections, particularly herpes simplex keratitis, are a classic contraindication because steroids suppress the immune response the eye needs to fight the virus. Uncontrolled glaucoma or a known history of strong steroid-pressure responses makes the risk calculation unfavorable. And for patients whose dry eye is mild and primarily a lubrication issue without significant inflammation, the risk-benefit ratio tilts against steroids because simpler interventions like preservative-free artificial tears, warm compresses, and omega-3 supplements may be enough.
Some clinicians use point-of-care testing for inflammatory markers on the eye surface to help decide whether a patient’s dry eye has enough of an inflammatory component to warrant steroids. One such test measures levels of a specific enzyme called MMP-9, which is elevated when the ocular surface is inflamed.
21PubMed Central. The Matrix Metalloproteinase 9 Point-of-Care Test in Dry EyeA positive result makes the case for anti-inflammatory therapy stronger, while a negative result might suggest that lubrication alone is a reasonable starting point. These tests are not universally available and are not required before prescribing steroids, but they represent a move toward more targeted treatment rather than a one-size-fits-all approach.